Cardiff Lexington Corporation · OTC:CDIX
Cardiff Lexington — Cardiff Lexingtn — Q2 2026 Earnings Presentation
9 slides from Cardiff Lexington's earnings presentation, Aug 12, 2026
Slide 1: Second Quarter 2026 Earnings Presentation
SECOND QUARTER 2026 EARNINGS PRESENTATION Wednesday, August 12, 2026 OTC: CDIX
Slide 2: Forward Looking Statements
FORWARD LOOKING STATEMENTS This presentation does not constitute or form part of and should not be construed as, an offer to sell or issue or the solici tation of an offer to buy or subscribe for securities of Cardiff Lexington (the “Company”) in any jurisdiction or an inducement to enter into inves
Slide 3: Executive Summary
EXECUTIVE SUMMARY Cardiff Lexington by the Numbers YTD ended June 30, 2026 Operational & Strategic Updates 12 Nova Ortho and Spine locations • Opened 12th Nova Ortho and Spine throughout Florida & Georgia Location in Tallahassee, FL $4.4 M • Expanding clinical and operational teams across Nova Ortho
Slide 4: Second Quarter & YTD 2026 Financial Highlights
SECOND QUARTER & YTD 2026 FINANCIAL HIGHLIGHTS Three Months Ended Six Months Ended 6/30/26 6/30/25 6/30/26 6/30/25 Revenue $2,159,557 $2,789,007 $4,381,837 $5,704,574 Cost of sales $977,242 $1,093,748 $1,881,467 $2,168,782 Gross profit $1,182,315 $1,695,259 $2,500,370 $3,535,792 Gross margin 54.7% 6
Slide 5: Balance Sheet Highlights
BALANCE SHEET HIGHLIGHTS Accounts Receivable Total Assets $23.7M $30.7M $29.1M $22.1M 12.31.25 6.30.26 12.31.25 6.30.26 7.2% Increase 5.5% Increase 5
Slide 6: Proven Business Model Supports Long-Term Strategy
PROVEN BUSINESS MODEL SUPPORTS LONG- TERM STRATEGY Proven Economic Model Demonstrated ability to drive growth and profitability in diverse economic markets and conditions Consistent Performance with Limited Working Capital Proven track record of driving return on invested capital Investing in Growth
Slide 7: Cardiff Lexington Q&A
we 4 CARDIFF LEXINGTON CORPORATION Q&A
Slide 8: Appendix
we 4 CARDIFF LEXINGTON CORPORATION APPENDIX
Slide 9: Reconciliation of Non-GAAP Metrics
RECONCILIATION OF NON-GAAP METRICS Three months ended Six months ended 6/30/26 6/30/25 6/30/26 6/30/25 Net Income (loss) before discontinued operations $(2,478,906) $(1,226,395) $(5,570,980) $(1,677,172) Adjustments to reconcile net income/(loss) to EBITDA Interest 2,137,419 1,836,072 4,048,156 2,82